Docoh
Loading...

ZYME Zymeworks

APP
Utility
Bispecific Antigen-binding Constructs Targeting HER2
30 Dec 21
Provided herein are biparatopic antigen-binding constructs that specifically bind HER2.
Nina E. Weisser, Gordon Yiu Kon NG, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
Filed: 24 Feb 21
GRANT
Utility
Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
28 Dec 21
The present disclosure provides light chain polypeptides that include a C-terminal extension, as well as antibodies and antibody conjugates containing such modified light chain polypeptides, where the C-terminal extension includes one or more cysteine residues.
John Babcook, James R. Rich, Jan Peter Bergqvist, Stuart Daniel Barnscher
Filed: 23 Dec 14
APP
Utility
Antigen-Binding Constructs Targeting HER2
23 Dec 21
Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2.
Eric Escobar-Cabrera, Leonard G. Presta
Filed: 3 May 21
GRANT
Utility
Checkpoint inhibitor bispecific antibodies
21 Dec 21
The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human PD-1, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
Michael Dewain Kalos, Yiwen Li, Dale Lincoln Ludwig, Yang Shen, Igor Edmondo Paolo D'Angelo, Gregory D Plowman
Filed: 9 Jul 18
APP
Utility
ANTI-PD-1/LAG3 Bispecific Antibodies
2 Dec 21
Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments.
Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING, Eric Escobar CABRERA, Genevieve DESJARDINS
Filed: 23 Jul 21
APP
Utility
ANTI-PD-1/LAG3 Bispecific Antibodies
25 Nov 21
Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments.
Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING, Eric Escobar CABRERA, Genevieve DESJARDINS
Filed: 23 Jul 21
APP
Utility
Antigen-Binding Polypeptide Constructs Comprising Kappa and Lambda Light Chains and Uses Thereof
18 Nov 21
Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain.
Dunja UROSEV, Stacey A.L. TOM-YEW, Leonard G. PRESTA, Mario SANCHES
Filed: 27 Apr 21
APP
Utility
ANTI-HER2 Biparatopic Antibody-drug Conjugates and Methods of Use
11 Nov 21
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer.
Kevin Hamblett, Rupert H. Davies, James R. Rich, Gerald J. Rowse, Vincent K.C. Fung, Stuart D. Barnscher
Filed: 23 Mar 21
GRANT
Utility
Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
2 Nov 21
Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain.
Dunja Urosev, Stacey A. L. Tom-Yew, Leonard G. Presta, Mario Sanches
Filed: 7 Oct 16
GRANT
Utility
Drug-conjugated bi-specific antigen-binding constructs
19 Oct 21
Bispecific antigen-binding constructs e.g., antibodies conjugated to drugs (ADCs), which bind CD3 and other cell-surface target antigen such as tumor antigens e.g., CD19, CDH3, HER2, HER3 and EGFR antigens and methods of use are disclosed.
Gordon Yiu Kon Ng, Leonard G. Presta, Thomas Spreter Von Kreudenstein
Filed: 15 Jul 16
GRANT
Utility
Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
19 Oct 21
The invention provides methods and systems of determining biopolymer profiles and correlations between structural units (residues) of a biopolymer based on sampling of the conformational space available to the molecule.
Paula I. Lario, Johannes Mullegger, Surjit B. Dixit, Tomas Rodinger, Powell Patrick Cheng Tan
Filed: 27 Jul 16
APP
Utility
Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
14 Oct 21
Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells.
Gordon Yiu Kon Ng, Surjit Bhimarao Dixit, Thomas Spreter von Kreudenstein, Nina E. Weisser
Filed: 19 Mar 21
APP
Utility
Engineered Immunoglobulin Heavy Chain-Light Chain Pairs and Uses Thereof
7 Oct 21
Provided are heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain.
Adam Louis Corper, Dunja Urosev, Stacey A.L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
Filed: 9 Jun 21
APP
Utility
STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN
9 Sep 21
The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g.
Thomas Spreter Von Kreudenstein, Eric Escobar-Cabrera, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon, Igor D'Angelo
Filed: 30 Nov 20
APP
Utility
Methods Using Monovalent Antigen Binding Constructs Targeting HER2
2 Sep 21
Provided herein are methods of use and treatment using a first or a first and second monovalent antigen-binding constructs targeting HER2.
Gordon Yiu Kon NG, Nina E. WEISSER, Grant Raymond WICKMAN
Filed: 17 Dec 20
APP
Utility
ANTI-HER2 Biparatopic Antibody-drug Conjugates and Methods of Use
26 Aug 21
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer.
Kevin HAMBLETT, Rupert H. DAVIES, James R. RICH, Gerald J. ROWSE, Vincent K.C. FUNG, Stuart D. BARNSCHER
Filed: 12 Mar 19
GRANT
Utility
Heteromultimers with reduced or silenced effector function
24 Aug 21
Provided herein are heteromultimer constructs with reduced or silenced effector function.
Eric Escobar-Cabrera
Filed: 30 May 14
GRANT
Utility
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
3 Aug 21
Provided are heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain.
Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
Filed: 14 Feb 18
GRANT
Utility
Anti-PD-1/LAG3 bispecific antibodies
27 Jul 21
Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments.
Laurence Fayadat-Dilman, Veronica Juan, Shireen Khan, Shaopeng Huang, Hua Ying, Eric Escobar Cabrera, Genevieve Desjardins
Filed: 31 Jan 19
APP
Utility
Methods of Using Bispecific Antigen-binding Constructs Targeting HER2
24 Jun 21
Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors.
Grant Raymond Wickman, Gordon Yiu Kon Ng, Nina E. Weisser
Filed: 25 Sep 20
Patents are sorted by USPTO publication date, most recent first